An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2014
At a glance
- Drugs PR 15 (Primary)
- Indications Atherosclerosis; Thrombosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors advanceCor
- 18 Oct 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Jan 2010 New trial record